Adam M. Brufsky, MD, PhD
Although new targeted therapies have been introduced in recent years for patients with advanced hormone receptor (HR)-positive breast cancer, questions remain on the most effective ways to use these treatments throughout the continuum of disease, according to experts who participated in an OncLive
Several multiparametric genomic assays have been developed to predict recurrence in patients with early-stage disease, but the panelists agreed that more research is needed to clarify how these assays predict the need for and response to chemotherapy. The panelists also discussed prospective strategies for individualizing treatment for locally advanced and metastatic HR-positive breast cancer based on recent clinical trial data for extended adjuvant endocrine therapy and combinations, including aromatase inhibitors (AIs), cyclin-dependent kinase (CDK) 4/6 inhibitors, selective estrogen receptor (ER) degraders, mTOR inhibitors, and PI3K inhibitors.
Multiparametric Genomic Assays
Panelists agreed that several multiparametric genomic assays that predict risk for recurrence can guide oncologists and patients when making clinical decisions for early-stage breast cancer. However, Mark E. Robson, MD
, stated that the inability to predict benefit from chemotherapy is a key shortcoming with many of the assays. “When it comes down to conversations with the patients, you want to know are they or are they not going to benefit from incremental therapy,” said Robson.
... to read the full story